ExamPat

Padmashri Ponnaluri

USPTO Patent Examiner·Active 2012 to 2024

Padmashri Ponnaluri is a USPTO patent examiner who has handled 54 ex parte reexaminations between 2012 and 2024. These reexams concentrate in Chemistry & Materials, Life Sciences & Consumer, and Physics & Instruments. ExamPat indexes the full prosecution record for each of these cases, including office-action grounds, certificate outcomes, and downstream PTAB and federal-circuit decisions.

Filings by year

8
12
6
13
6
14
4
15
4
16
4
17
5
18
5
19
1
20
4
21
3
22
5
23
2
24

Technology mix

Chemistry & Materials37 (65%)
Life Sciences & Consumer18 (32%)
Physics & Instruments2 (4%)

Compare against all examiners

Eight side-by-side metrics: case volume, pendency, OAs per reexam, rejection mix, SNQ denial rate, certification rate, and PTAB appeal rate, with a Δ column showing where this examiner runs higher or lower than the corpus.

  • Average and median pendency, both for this examiner and the corpus
  • Rejection basis split (102 / 103 / 112) head-to-head
  • Certification, SNQ denial, and PTAB appeal rates

Certificate outcome distribution

How this examiner's certificates split across the six possible outcomes: all claims confirmed, confirmed with amendment, confirmed with new claims, mixed, or all claims canceled. Includes share comparison to the corpus distribution.

  • Count and share for each of the six outcome buckets
  • Δ vs. corpus distribution in percentage points
  • Useful for setting realistic patent-owner expectations

Event-to-event timing

Median time for this examiner's cases at each prosecution stage, from filing to first office action, filing to NIRC, and filing to certificate, with corpus comparison and sample size.

  • Median in months per transition
  • Side-by-side with the corpus median
  • n column showing how many of this examiner's cases completed each transition

vs. all examiners

Certificate outcome distribution

Event-to-event timing (median)

Recent reexaminations (showing 25 of 54)

View all in dashboard →
Control #FiledPatentTitlePendencyStatus
90/019,445Apr 11, 20249,951,378NOVEL COMPOSITIONS, METHODS AND KITS FOR REAL TIME POLYMERASE CHAIN REACTION (PCR)15 moClosed
90/019,379Jan 17, 202411,608,491SUSPENSION SYSTEM FOR ADENO ASSOCIATED VIRUS PRODUCTION13 moClosed
90/019,313Nov 30, 202311,583,556MODIFIED CELLS AND METHODS OF THERAPY22 moClosed
90/019,297Nov 8, 202311,680,252PET HYDROLASE HAVING IMPROVED THERMAL STABILITY8 moClosed
90/019,225Jul 6, 202310,327,400METHODS FOR IDENTIFYING CROSSES FOR USE IN PLANT BREEDING11 moClosed
90/015,234May 16, 202311,623,941SEPARATION METHOD11 moClosed
90/015,214Mar 22, 202310,995,338METHOD FOR REMOVING GENETIC LINKAGE IN A PLANT12 moClosed
90/015,171Nov 30, 202211,089,765GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)12 moClosed
90/015,048Jun 7, 202211,291,723SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION18 moClosed
90/015,047Jun 7, 202211,351,252SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION14 moClosed
90/014,910Nov 23, 202110,913,768COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS9 moClosed
90/014,883Oct 15, 202110,829,737Chimeric Receptor with NKG2D Specificity for Use in Cell Therapy Against Cancer and Infectious Disease17 moClosed
90/014,779Jun 21, 20219,511,092A Chimeric Receptor With NKG2D Specificity For Use In Cell Therapy Against Cancer And Infectious Disease19 moClosed
90/014,705Mar 23, 202110,953,090SELECTIVELY ALTERING MICROBIOTA FOR IMMUNE MODULATION42 moClosed
90/014,449Feb 11, 202010,406,226METHOD OF MANUFACTURING VEGF ANTAGONIST FUSION PROTEINS45 moClosed
90/014,423Dec 20, 20197,588,755DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING HUMAN FIBROBLAST INTERFERON-LIKE POLYPEPTIDES51 moClosed
90/014,395Oct 24, 201910,022,435Nucleic Acid Vaccines14 moClosed
90/014,318Jun 19, 20199,428,767ENHANCED NUCLEIC ACID CONSTRUCTS FOR EUKARYOTIC GENE EXPRESSION17 moClosed
90/014,320Jun 19, 20199,574,209ENHANCED NUCLEIC ACID CONSTRUCTS FOR EUKARYOTIC GENE EXPRESSION13 moClosed
90/014,299May 3, 20199,745,381BISPECIFIC SCFV IMMUNOFUSION (BIF)18 moClosed
90/014,218Oct 5, 20187,625,558COMPOSITIONS AND METHODS OF TREATING TUMORS6 moClosed
90/014,167Aug 17, 20189,872,900NUCLEIC ACID VACCINES9 moClosed
90/014,181Aug 8, 20188,293,779MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY13 moClosed
90/014,165Jul 13, 20189,745,381Bispecific ScFV Immunofusion (BIf)28 moClosed
90/014,140May 18, 20188,962,271FRUCTOSYL PEPTIDYL OXIDASE16 moClosed

Other USPTO reexam examiners

Get the full reexam analytics

Compare Padmashri Ponnaluri against the full corpus, see the certificate-outcome split, drill into event timing, filter the case list, and export. Free to sign up.